Why Zepbound (Tirzepatide) Causes Constipation: The Mechanism Explained

At a glance

• Incidence in trials: 5.9% at 10 mg, 7.2% at 15 mg (vs. 1.7% placebo) in SURMOUNT-1
• Typical onset: Within the first 4 to 8 weeks, often during dose-escalation phases
• Primary mechanism: GLP-1 receptor activation on enteric and vagal neurons slows propulsive colonic motility
• Contributing factor: Reduced food and fluid intake from appetite suppression
• First-line management: Soluble fiber supplementation, increased water intake, osmotic laxatives (PEG 3350 or magnesium citrate)
• When to escalate: No bowel movement for 4+ days, abdominal distension, vomiting, or severe pain
• Discontinuation threshold: Bowel obstruction, fecal impaction, or refractory symptoms despite maximal conservative treatment

How Tirzepatide Reaches the Gut

Tirzepatide is a synthetic peptide that binds two incretin receptors: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). After subcutaneous injection, it reaches peak plasma concentration in about 8 to 72 hours and has a half-life of approximately 5 days. That long half-life means the drug exerts continuous receptor activation between weekly doses, with no daily "off" period for the gut to reset to its baseline motility pattern.

The GLP-1 receptor component is the primary driver of gastrointestinal side effects, including constipation. GIP receptor activation appears to have less direct impact on colonic transit, though it may contribute to overall changes in gut hormone signaling.

The GLP-1 Receptor and Colonic Motility

GLP-1 receptors are expressed in three locations that matter for bowel function:

Enteric nervous system. The myenteric and submucosal plexuses (the nerve networks embedded in the intestinal wall) contain GLP-1 receptors. When tirzepatide activates these receptors, it inhibits the release of acetylcholine from excitatory motor neurons. Acetylcholine is the primary neurotransmitter that drives peristaltic contractions. Less acetylcholine means weaker and less frequent propulsive waves pushing stool forward through the colon.

Vagal afferent neurons. GLP-1 receptors on vagal nerve endings in the gut send signals to the brainstem's nucleus tractus solitarius (NTS). Activation of these afferents triggers a central feedback loop that suppresses parasympathetic outflow to the colon. The result: the brain actively turns down the "push" signal to the large intestine. Research on GLP-1 receptor agonists confirms this vagal-mediated slowing of colonic transit is dose-dependent.

Smooth muscle cells. Some evidence suggests GLP-1 receptors exist directly on colonic smooth muscle, though their density is lower than in the enteric nervous system. Direct smooth muscle relaxation may play a minor additional role.

The combined effect is a measurable reduction in colonic transit time. In motility studies of GLP-1 receptor agonists, colonic transit has been shown to slow by 6 to 12 hours compared to baseline, with the most pronounced effect in the ascending and transverse colon segments where water absorption from stool is most active.

Why Slower Transit Creates Hard, Infrequent Stools

This is the critical connection. The colon's primary job is absorbing water from intestinal contents. Stool that moves through the colon at normal speed (12 to 36 hours of colonic transit) arrives at the rectum with appropriate water content, roughly 70 to 75% water by weight.

When tirzepatide slows transit, stool sits in the ascending and transverse colon for longer than normal. The colonic epithelium continues absorbing water at its usual rate, but now it has more time to do so. The result: stool arriving at the sigmoid colon and rectum is drier, harder, and more compact. That stool is more difficult to propel and more difficult to evacuate.

Patients typically describe the constipation as infrequent stools (every 3 to 5 days instead of daily), hard or pellet-like consistency, and a sense of incomplete evacuation. This matches a Rome IV slow-transit constipation pattern rather than an outlet obstruction pattern.

The Dose-Escalation Connection

The SURMOUNT-1 trial showed constipation rates increasing with dose: 3.9% at 5 mg, 5.9% at 10 mg, and 7.2% at 15 mg. This dose-response relationship makes pharmacological sense. Higher doses produce greater GLP-1 receptor occupancy in the enteric nervous system, which means stronger inhibition of excitatory neurotransmitter release and slower colonic contractions.

Most patients report that constipation peaks during the first 2 to 4 weeks after each dose increase. The body partially adapts through receptor desensitization (GLP-1 receptors undergo some degree of tachyphylaxis with sustained activation), which is why many patients find that constipation improves after 4 to 8 weeks at a stable dose. In the SURMOUNT trials, constipation was the primary reason for dose reduction in approximately 0.3% of patients, and <1% discontinued due to constipation alone.

The Reduced-Intake Factor

Tirzepatide produces significant appetite suppression through both central GLP-1 receptor activation (hypothalamic satiety signaling) and delayed gastric emptying. Patients on tirzepatide eat substantially less food. In SURMOUNT-1, caloric intake dropped by an estimated 20 to 35% from baseline.

Less food intake means less fiber reaching the colon. Less fluid intake (a common secondary effect of reduced appetite) means less water available for stool formation. Both of these compound the direct motility-slowing effect. A patient who was previously having regular bowel movements on a 2,200-calorie diet with 25g of fiber may now be eating 1,500 calories with 12g of fiber and drinking 20% less water. That alone would cause constipation in many people, even without the pharmacological motility effect.

This is why dietary modifications (increasing fiber and water intake specifically, independent of calorie reduction) are the first-line intervention.

How This Differs From Opioid-Induced Constipation

Patients sometimes compare tirzepatide constipation to opioid-induced constipation (OIC). The mechanisms overlap but differ in an important way. Opioids act on mu-receptors in the enteric nervous system to inhibit both secretion and motility. GLP-1 receptor activation primarily affects motility, with a smaller effect on intestinal secretion. This means tirzepatide constipation is generally less severe than OIC at equivalent levels of transit slowing, and it responds better to osmotic laxatives (which work by drawing water into the lumen) because the secretory machinery is relatively intact.

Stimulant laxatives (bisacodyl, senna) work by triggering propulsive contractions. They can be effective for tirzepatide constipation, but osmotic agents (PEG 3350, magnesium citrate) are preferred first-line because they address the core problem: stool that has become too dry from prolonged colonic contact time. The AGA's clinical guidelines for chronic constipation support this stepwise approach.

When the Mechanism Signals a Problem

In rare cases (<0.5% in trials), tirzepatide's motility-slowing effect can contribute to more serious complications:

• Fecal impaction: Extremely hard stool lodges in the rectum and cannot be evacuated voluntarily. Requires manual disimpaction or enema.
• Ileus: Near-complete cessation of colonic motility. Presents with abdominal distension, absent bowel sounds, and vomiting. Requires medical evaluation and possible hospitalization.
• Intestinal obstruction: Particularly concerning in patients with pre-existing adhesions, strictures, or diverticular disease where slowed motility increases the risk of a mechanical blockage.

Any patient on tirzepatide who has not had a bowel movement in 5+ days, develops progressive abdominal distension, or experiences vomiting should contact their prescriber immediately. These symptoms require clinical evaluation to rule out obstruction.

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038

2. Zepbound (tirzepatide) prescribing information. Eli Lilly and Company. 2023. FDA label

3. Halawi H, Khemani D, Eckert D, et al. Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial. Lancet Gastroenterol Hepatol. 2017;2(12):890-899. doi:10.1016/S2468-1253(17)30285-6

4. Hellstrom PM, Naslund E, Edholm T, et al. GLP-1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome. Neurogastroenterol Motil. 2008;20(6):649-659. doi:10.1111/j.1365-2982.2007.01079.x

5. Bharucha AE, Dorn SD, Lembo A, Pressman A. American Gastroenterological Association medical position statement on constipation. Gastroenterology. 2013;144(1):211-217. doi:10.1053/j.gastro.2012.10.016

6. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183